poudre et solvant pour solution pour perfusion
Sponsors
Octapharma AG, Institut Bergonie, Centre Hospitalier Universitaire De Nantes
Conditions
Acquired Antithrombin Deficiency (Heparin Resistance)Congenital antithrombin deficiencyResectablenon-metastatic soft-tissue sarcoma (STS)staphylococcal endocarditis
Phase 3
CIRSARC : PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE
SOFT-TISSUE SARCOMAS
RecruitingCTIS2023-509489-39-00
Start: 2019-02-05Target: 351Updated: 2025-12-22
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Active, not recruitingCTIS2023-507560-39-00
Start: 2024-11-07Target: 34Updated: 2025-12-19
A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery
RecruitingCTIS2024-515830-34-00
Start: 2023-02-14Target: 28Updated: 2025-09-22
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
Not yet recruitingCTIS2024-518018-22-00
Target: 422Updated: 2025-08-28